![]() |
|
|
Vol. 28, Issue 9, 1135-1140, September 2000
Departments of Biopharmaceutical Sciences (M.J.D., K.M.G., K.M.G.)
and Anesthesia (A.T.G.), University of California-San Francisco,
Schools of Pharmacy and Medicine, San Francisco, California; and
Department of Physiology (D.D.F.L.), UCLA School of Medicine, Los
Angeles, California
Nucleoside transporters that mediate cellular uptake of
therapeutic nucleoside analogs are major determinants of the
pharmacokinetic properties of these compounds. Understanding the
substrate selectivity of these transporters is critical in the
development of therapeutic nucleoside analogs with optimal
pharmacokinetic properties, including high oral bioavailability and
tissue-specific distribution. In general, substrate selectivity of
nucleoside transporters has been evaluated indirectly by inhibition
studies. The purpose of this study was to directly measure the
transport of nucleoside analogs by the sodium-coupled
pyrimidine-selective transporter rCNT1 using electrophysiology methods.
We used a two-electrode voltage clamp assay to investigate the
substrate selectivity of rCNT1; 19 structurally diverse nucleosides and
nucleoside analogs were studied. Uridine-induced currents in
voltage-clamped oocytes expressing rCNT1 were sodium-, voltage-, and
concentration-dependent (K0.5 = 21 µM), and were blocked by adenosine. Uridine-induced currents
increased ~5-fold upon hyperpolarization of membrane potential from
10 to
150 mV. Uridine, thymidine, and cytidine induced currents in
rCNT1-expressing oocytes, whereas guanosine, inosine, and adenosine did
not. Uridine, deoxyuridine, and cytidine analogs with modifications at
the 3-, 4-, or 5-position were found to be substrates of rCNT1, whereas
uridine and cytidine analogs modified at the 6-position were not. In
addition, it was found that the 5'-hydroxyl group of the sugar is not
required for transport by rCNT1. These results enhance our
understanding of the structural basis for substrate selectivity of
nucleoside transporters and should prove useful in the development of
therapeutic nucleoside analogs.
This article has been cited by other articles:
![]() |
K. M. Smith, A. M. L. Ng, S. Y. M. Yao, K. A. Labedz, E. E. Knaus, L. I. Wiebe, C. E. Cass, S. A. Baldwin, X.-Z. Chen, E. Karpinski, et al. Electrophysiological characterization of a recombinant human Na+-coupled nucleoside transporter (hCNT1) produced in Xenopus oocytes J. Physiol., August 1, 2004; 558(3): 807 - 823. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. M. Larrayoz, F. J. Casado, M. Pastor-Anglada, and M. P. Lostao Electrophysiological Characterization of the Human Na+/Nucleoside Cotransporter 1 (hCNT1) and Role of Adenosine on hCNT1 Function J. Biol. Chem., March 5, 2004; 279(10): 8999 - 9007. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Gerstin, M. J. Dresser, and K. M. Giacomini Specificity of human and rat orthologs of the concentrative nucleoside transporter, SPNT Am J Physiol Renal Physiol, August 1, 2002; 283(2): F344 - F349. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. Mata, J. M. Garcia-Manteiga, M. P. Lostao, S. Fernandez-Veledo, E. Guillen-Gomez, I. M. Larrayoz, J. Lloberas, F. J. Casado, and M. Pastor-Anglada Role of the Human Concentrative Nucleoside Transporter (hCNT1) In the Cytotoxic Action of 5[Prime]-Deoxy-5-fluorouridine, an Active Intermediate Metabolite of Capecitabine, a Novel Oral Anticancer Drug Mol. Pharmacol., June 1, 2001; 59(6): 1542 - 1548. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Soler, R. Valdes, J. Garcia-Manteiga, J. Xaus, M. Comalada, F. J. Casado, M. Modolell, B. Nicholson, C. MacLeod, A. Felipe, et al. Lipopolysaccharide-induced Apoptosis of Macrophages Determines the Up-regulation of Concentrative Nucleoside Transporters Cnt1 and Cnt2 through Tumor Necrosis Factor-alpha -dependent and -independent Mechanisms J. Biol. Chem., August 3, 2001; 276(32): 30043 - 30049. [Abstract] [Full Text] [PDF] |
||||